Diatech Pharmacogenetics
Diatech Pharmacogenetics is an Italian molecular diagnostics company that develops CE-IVD marked kits and the Myriapod® system for precision oncology and pharmacogenetics testing, serving clinical laboratories, hospitals, and pharmaceutical partners across Europe and the MEA region.
- Company typePrivate
- Founded1999
- HeadquartersJesi, Italy
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Diatech Pharmacogenetics does
Diatech Pharmacogenetics is an Italian molecular diagnostics company headquartered in Jesi, Italy, specializing in precision medicine for oncology and pharmacogenetics. Founded in 1996, the company develops and distributes CE-IVD marked in vitro diagnostic kits built on Agena Bioscience's MassARRAY technology platform, with its flagship Myriapod® system enabling highly multiplexed analysis of SNPs and actionable mutations in a single assay and delivering results from patient DNA to therapy selection in under one day. The product portfolio spans solid tumor diagnostics (KRAS, NRAS, BRAF, EGFR, ALK for colon, lung, and melanoma), blood cancer testing (NPM1 for AML, CML monitoring), and pharmacogenetics panels (DPYD, UGT1A1, CYP2D6, TPMT/NUDT15) to guide chemotherapy dosing, supplemented by the Labcycler PCR thermal cycler instrument and an NGS module. The company also operates four wholly-owned subsidiaries covering distribution, gene synthesis, healthcare IT software, and small-molecule discovery.
Diatech serves hospital and independent clinical laboratories, oncology and hematology departments, and pharmaceutical partners across Italy, Germany, the UK, France, and the MEA region. Its go-to-market combines direct B2B enterprise sales through a registered customer portal with channel partnerships (Merck Serono for MEA distribution, Agena Bioscience for European MassARRAY Dx PLUS rollout) and technology integrations with Illumina, Revvity, and ArcherDX. Revenue mechanics are driven by one-time kit and instrument sales, licensing/royalty arrangements with technology partners, and quote-based pricing negotiated with institutional buyers. The company is privately held following PE transactions by Alto Partners (40% stake, 2021) and TA Associates (minority stake, 2023) and maintains EN ISO 9001, EN ISO 13485, and IVDR certifications.
Diatech Pharmacogenetics firmographics
Firmographics- Name
- Diatech Pharmacogenetics
- Legal name
- Diatech Pharmacogenetics S.r.l.
- Website
- https://diatechpharmacogenetics.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Diatech Pharmacogenetics is an Italian molecular diagnostics company that develops CE-IVD marked kits and the Myriapod® system for precision oncology and pharmacogenetics testing, serving clinical laboratories, hospitals, and pharmaceutical partners across Europe and the MEA region.
- Ownership category
- akta.pro rank
Diatech Pharmacogenetics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Diatech Pharmacogenetics is headquartered
LocationHeadquarters
- HQ city
- Jesi
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Diatech Pharmacogenetics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Molecular Diagnostic Kits and Tests: Sale of CE-IVD marked diagnostic kits including Myriapod product line for solid tumor, blood cancer, and pharmacogenetics testing. The kits analyze tens of mutations in a single session and provide results from patient's DNA to personalized therapy choice in less than one day.
- Labcycler Instruments: Sale of Labcycler PCR thermal cycler instruments designed for research, diagnostic and biotechnology laboratories. The instrument is a compact and highly reliable PCR thermal cycler with advanced thermal control and interchangeable block system.
- RAS Biomarker Testing: Diagnostic testing services for RAS biomarkers in colorectal cancer, particularly in partnership with Merck for MEA region expansion.
- OEM/Embedded Technology Licensing: Technology partnerships with Illumina, Revvity, ArcherDX, and Agena Bioscience involving integration and distribution of diagnostic solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | B2B enterprise pricing through reserved customer area |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels9 records
Diatech Pharmacogenetics product offering
Product offeringCore offering
Diatech Pharmacogenetics develops, manufactures, and distributes CE-IVD marked molecular diagnostic kits and instruments for precision oncology and pharmacogenetics. Its flagship Myriapod® system enables identification of SNPs and actionable mutations (KRAS, NRAS, BRAF, EGFR, ALK) in solid tumors, blood cancers, and pharmacogenetic applications, delivering personalized therapy recommendations in less than one day. The company also manufactures the Labcycler PCR thermal cycler instrument for research and diagnostic laboratories.
Product overview
Diatech Pharmacogenetics is an Italian molecular diagnostics company providing pharmacogenetic testing solutions dedicated to personalized and predictive medicine, with priority focus on anti-cancer treatments. The company's portfolio centers on the Myriapod® system, a CE-IVD marked in vitro diagnostic line that enables identification of genetic biomarkers affecting drug response with results in less than one day. The Myriapod ecosystem includes multiple product lines: Myriapod NGS for next-generation sequencing, Myriapod® Dx PLUS for multiplexed mutation analysis in solid tumors (KRAS, NRAS, BRAF, EGFR, ALK), Easy and Easy PGX for pharmacogenetics testing, Helix for NGS library preparation, Microsatelliti for microsatellite instability detection, Realquant for quantitative PCR, and Response for treatment response biomarkers. The company also distributes the Labcycler PCR thermal cycler instrument. Products support solid tumor testing, blood cancer diagnostics, and pharmacogenetics across oncology applications.
Differentiator
Problem solved
Functional benefit
Brands
- Myriapod: CE-IVD in vitro diagnostic line that permits identification of SNPs which could give adverse response to drugs used for specific neoplastic pathology treatment. Enables analysis of tens of mutations in a single session.
Products and services
- Myriapod® CE-IVD marked in vitro diagnostic system enabling identification of SNPs that could give adverse response to drugs used for specific neoplastic pathology treatment. Analyzes tens of mutations in a single session, delivering results from patient DNA to personalized therapy choice in less than one day. Targeted at hospital and clinical laboratories performing molecular diagnostics.
- Myriapod® Dx PLUS CE-IVD marked assay system providing parallel analysis of frequently observed and actionable mutations in colon, lung, and melanoma tumors using MassARRAY technology. Tests for KRAS, NRAS, BRAF, EGFR, and ALK genes. Designed for oncology and clinical diagnostic laboratories.
- Myriapod NGS Next-generation sequencing module within the Myriapod ecosystem for advanced genomic analysis and molecular diagnostics in oncology applications.
- Easy PGX Pharmacogenetics testing product line for predicting drug response and adverse reactions based on genetic variants, focused on anti-cancer treatments including 5-FU/capecitabine (DPYD), irinotecan (UGT1A1), tamoxifen (CYP2D6), and thiopurine therapy (TPMT/NUDT15).
- Easy Product line for molecular diagnostics testing within the Diatech Pharmacogenetics portfolio, covering core molecular diagnostic applications.
- Helix Product line within the Myriapod ecosystem for NGS library preparation and genomic analysis.
- Microsatelliti Product line for microsatellite instability testing in cancer diagnostics.
- Realquant Product line for quantitative real-time PCR analysis in molecular diagnostics.
- Response Product line focused on biomarkers for monitoring and predicting treatment response in oncology.
- Labcycler Compact and highly reliable PCR thermal cycler designed by German engineering and manufactured by Diatech Pharmacogenetics. Supports daily needs of research, diagnostic, and biotechnology laboratories with advanced thermal control, interchangeable block system, and intuitive touch screen interface.
Quantifiable outcome
- Results from patient DNA to personalized therapy choice in less than one day
- +4 more outcomes
Companies that use Diatech Pharmacogenetics
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Diatech Pharmacogenetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
Diatech Pharmacogenetics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and strategic.
- Merck Serono Middle East Ltd. (affiliates of Merck KGaA)coreExpanded collaboration to improve patient access to RAS biomarker testing for colorectal cancer in the Middle East and Africa regions. The partnership aims to advance healthcare solutions and enable timely, accurate genetic testing for metastatic colorectal cancer patients across the MEA region.
- Agena BiosciencecoreStrategic partnership for development and commercial launch of CE-IVD marked MassARRAY Dx PLUS assays for gene-specific mutation testing. Diatech built its CE-IVD marked Myriapod system and assays based on Agena Bioscience's MassARRAY technology.
- Illumina, Inc.strategicGlobal genomics and human health partnership. Illumina develops DNA sequencing and array-based life sciences technologies enabling research discovery and personalized health. Diatech integrates genomic solutions across oncology applications.
- Revvity, Inc.strategicScience-solutions partnership providing instruments, reagents, assays and software. Revvity offers global workflow capabilities from research to clinical applications in pharma, biotech, diagnostics, and healthcare.
- ArcherDX, Inc.strategicGenomic analysis partnership advancing precision oncology through products and services leveraging proprietary Anchored Multiplex PCR (AMP) chemistry and informatics platform for advanced detection of gene fusions, variants, and biomarkers.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Diatech Pharmacogenetics competitors and assessment
Company assessmentBroad incumbents
- Hologic: Major molecular diagnostics and women's health company with IVD kits sold globally. Comparable as an established IVD kit manufacturer with regulatory expertise, though with broader product portfolio and stronger US footprint.
- Qiagen: Global molecular diagnostics and sample-preparation leader with oncology and pharmacogenetics test menus. Comparable because both sell IVD molecular diagnostic kits to clinical labs and run parallel PCR- and NGS-based workflows, though Qiagen operates at much broader scale.
- NeoGenomics: US-based oncology-focused clinical laboratory and IVD provider offering molecular and pharmacogenomic testing. Comparable because both serve oncologists and hematologists with molecular biomarker testing for therapy selection, though NeoGenomics operates primarily as a reference lab rather than a kit vendor.
- Bio-Techne: Diagnostics and life-science reagents company with a molecular diagnostics portfolio including ExoDx and protein biomarker assays. Comparable as a B2B IVD kit vendor serving clinical labs, though with a broader reagents portfolio and US-centric distribution.
- Myriad Genetics: Established molecular diagnostics company with oncology and pharmacogenetics test offerings. Comparable as a long-standing IVD molecular diagnostics player serving oncologists, though with a US-centric focus and broader hereditary cancer testing franchise.
- Cepheid (Danaher): Subsidiary of Danaher operating the GeneXpert molecular diagnostics platform. Comparable as a global molecular IVD vendor with oncology and infectious disease menus sold to hospital labs, though at much larger scale and with broader regulatory clearances.
Direct peers
- Caris Life Sciences: Molecular diagnostics and precision oncology company offering comprehensive tumor profiling. Comparable as a precision oncology diagnostics provider offering molecular profiling for therapy selection, though Caris operates primarily as a reference lab rather than selling kits.
- HTG Molecular Diagnostics: Developer of molecular profiling technologies and assays for oncology applications. Direct peer because both target clinical labs with multiplexed gene-expression and mutation profiling assays for solid tumor and hematology applications.
- Agena Bioscience: Developer of the MassARRAY technology on which Diatech's Myriapod system is built. Direct peer because both commercialize MassARRAY-based CE-IVD diagnostic assays for oncology mutation testing, including the jointly launched MassARRAY Dx PLUS line.
- Veracyte: Molecular diagnostics company focused on oncology genomic testing. Comparable as a developer of molecular IVD tests for cancer diagnosis and treatment selection, with similar target customer base of hospital pathology labs and oncologists.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Diatech Pharmacogenetics social profiles
Digital presenceDiatech Pharmacogenetics compliance and trust
Trust signalCompliance3 records
Diatech Pharmacogenetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Diatech Pharmacogenetics leadership team
Management profileNumber of profiles
Profiles5 records
Diatech Pharmacogenetics subsidiaries and ownership
Company hierarchySubsidiaries4 records
Diatech Pharmacogenetics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Diatech Pharmacogenetics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Diatech Pharmacogenetics
What does Diatech Pharmacogenetics do?
Diatech Pharmacogenetics develops, manufactures, and distributes CE-IVD marked molecular diagnostic kits and instruments for precision oncology and pharmacogenetics. Its flagship Myriapod® system enables identification of SNPs and actionable mutations (KRAS, NRAS, BRAF, EGFR, ALK) in solid tumors, blood cancers, and pharmacogenetic applications, delivering personalized therapy recommendations in less than one day. The company also manufactures the Labcycler PCR thermal cycler instrument for research and diagnostic laboratories.
Is Diatech Pharmacogenetics a public or private company?
Diatech Pharmacogenetics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Diatech Pharmacogenetics founded?
Diatech Pharmacogenetics was founded in 1999. It employs 51 to 100 people.
Where is Diatech Pharmacogenetics based?
Diatech Pharmacogenetics is headquartered in Jesi, Italy, in the Europe region.
How does Diatech Pharmacogenetics make money?
Four revenue lines are on record. Molecular Diagnostic Kits and Tests are the primary driver. The others are labcycler Instruments, RAS Biomarker Testing and OEM/Embedded Technology Licensing.
Who are Diatech Pharmacogenetics's main competitors?
Broad incumbents on record are Hologic, Qiagen, NeoGenomics, Bio-Techne, Myriad Genetics and Cepheid (Danaher). Direct peers are Caris Life Sciences, HTG Molecular Diagnostics, Agena Bioscience and Veracyte.
Does Diatech Pharmacogenetics have an API?
No public API is recorded for Diatech Pharmacogenetics.
What industry is Diatech Pharmacogenetics in?
Diatech Pharmacogenetics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.